Search - tctmd.com

Displaying 21 - 40 of 51

Sort: Relevancy | Date

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

GRACE Performs Poorly in Ethnic Minorities With NSTEMI, Study Finds

L.A. McKeown

March 01, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

Advertisement

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

GRACE Performs Poorly in Ethnic Minorities With NSTEMI, Study Finds

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Cumulative Burden of LDL Cholesterol Increases CHD Risk

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

CHD Mortality Significantly Elevated in Patients With Severe FH

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content